Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales

• DOI: 10.1016/j.vaccine.2022.10.041
• Publication Date: 2022-10-31T12:47:58Z
• Authors: David Hodgson; Mihaly Koltai; Fabienne Krauer; Stefan Flasche; Mark Jit; Katherine E. Atkins
• Keywords: Pneumovirinae; Pneumovirus

Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new potentially longer-lasting antibody, Nirsevimab, showed promising results phase IIb/III trials. We evaluate the cost-effectiveness Nirsevimab intervention programmes England Wales. used dynamic model for RSV transmission, calibrated data considered suite potential programmes, including administration all neonates (year-round); born during season (seasonal); or plus less than six months old before start (seasonal + catch-up). If administered seasonally at birth, we found that would have be priced £63 per dose least 50% certainty it could cost-effectively replace current Palivizumab programme, using an ICER threshold £20,000/QALY. An extended seasonal programme which includes pre-season catch-up becomes optimal strategy purchasing price £32/dose certainty. At £5-32, annual implementation costs as high £2 million switch year-round optimal. has cost-effective Wales not use high-risk